Elemensis Lifesciences Private Limited
Pharmaceutical company specializing in trading medicaments and antibiotics, established in 2018 in Delhi.
2018 | Delhi (India) | Active
Elemensis Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.15 M
- Company Age 6 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 8.58%
- Profit Growth 38.19%
- Ebitda -145.62%
- Net Worth 27.29%
- Total Assets -3.63%
About Elemensis Lifesciences
Elemensis Lifesciences Private Limited (ELPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 July 2018 (Six years and seven months 21 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Gaurav Tekwani and Vanika Tekwani serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909DL2018PTC336304
- Company No.
336304
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jul 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Pharma
Who are the key members and board of directors at Elemensis Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gaurav Tekwani  | Director | 09-Jul-2018 | Current |
| Vanika Tekwani | Director | 12-Jul-2021 | Current |
Financial Performance of Elemensis Lifesciences.
Elemensis Lifesciences Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 8.58% increase. The company also saw a substantial improvement in profitability, with a 38.19% increase in profit. The company's net worth Soared by an impressive increase of 27.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elemensis Lifesciences?
In 2021, Elemensis Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Elemensis Lifesciences?
Unlock and access historical data on people associated with Elemensis Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elemensis Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elemensis Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
